跳到正文
原文
FDA · 新闻稿·· 6 天前精选AI 评分80

和誉医药研发、默克授权的匹米替尼获FDA批准用于TGCT

PIMJETMI® (pimicotinib) Developed by Abbisko Therapeutics and Licensed by Merck KGaA, Darmstadt, Germany Receive U.S. FDA Approval for TGCT - News-Graphic.com

AI 导读

和誉医药研发、由默克(Merck KGaA, Darmstadt, Germany)授权的PIMJETMI(pimicotinib,匹米替尼)获美国FDA批准,用于治疗腱鞘巨细胞瘤(TGCT)。

来源:FDA · 新闻稿 · news.google.com